Yayın:
Metastatic gastric cancer treatment: A little slow but worthy progress

Basit Görünüm
dc.contributor.authorO'Neil, Bert H.
dc.contributor.buuauthorKanat, Özkan
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıbbi Onkoloji Ana Bilim Dalı
dc.contributor.scopusid55881548500
dc.date.accessioned2022-06-21T07:24:14Z
dc.date.available2022-06-21T07:24:14Z
dc.date.issued2013-03
dc.description.abstractMetastatic gastric cancer is incurable and remains one of the leading causes of cancer-related deaths around the world. Despite the significant progress in its systemic treatment, metastatic gastric cancer is still a major therapeutic challenge for oncologists. Newer chemotherapy regimens and the addition of molecularly targeted agents to chemotherapy seem to provide better clinical outcomes for patients with metastatic gastric cancer. The objective of this article is to review the current treatment approach for this formidable disease.
dc.identifier.citationKanat, Ö ve O'Neil, BH. (2013). "Metastatic gastric cancer treatment: A little slow but worthy progress". Medical Oncology, 30(1).
dc.identifier.doi10.1007/s12032-013-0464-4
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue1
dc.identifier.pubmed23335104
dc.identifier.scopus2-s2.0-84880626824
dc.identifier.urihttps://doi.org/10.1007/s12032-013-0464-4
dc.identifier.urihttps://link.springer.com/article/10.1007/s12032-013-0464-4
dc.identifier.urihttp://hdl.handle.net/11452/27330
dc.identifier.volume30
dc.identifier.wos000316800800140
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherHumana
dc.relation.collaborationYurt dışı
dc.relation.journalMedical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOncology
dc.subjectGastric cancer
dc.subjectChemotherapy
dc.subjectTargeted treatment
dc.subjectGastroesophageal junction adenocarcinoma
dc.subjectPhase-II trial
dc.subjectChemotherapy-naive patients
dc.subjectFolinic acid
dc.subjectTargeted therapies
dc.subject1st-line treatment
dc.subjectPrognostic model
dc.subjectPlus cisplatin
dc.subjectDocetaxel
dc.subjectFluorouracil
dc.subject.emtreeBevacizumab
dc.subject.emtreeCapecitabine
dc.subject.emtreeCetuximab
dc.subject.emtreeCisplatin
dc.subject.emtreeDocetaxel
dc.subject.emtreeDoxorubicin
dc.subject.emtreeEpidermal growth factor receptor 2
dc.subject.emtreeEpirubicin
dc.subject.emtreeEtoposide
dc.subject.emtreeEverolimus
dc.subject.emtreeFluorouracil
dc.subject.emtreeFolinic acid
dc.subject.emtreeGimeracil plus oteracil potassium plus tegafur
dc.subject.emtreeIrinotecan
dc.subject.emtreeMethotrexate
dc.subject.emtreeOxaliplatin
dc.subject.emtreePanitumumab
dc.subject.emtreePhosphatidylinositol 3 kinase
dc.subject.emtreePlacebo
dc.subject.emtreeTrastuzumab
dc.subject.emtreeVasculotropin
dc.subject.emtreeVasculotropin receptor 1
dc.subject.emtreeVasculotropin receptor 2
dc.subject.emtreeAntineoplastic agent
dc.subject.emtreeAcne
dc.subject.emtreeAnemia
dc.subject.emtreeAntiangiogenic therapy
dc.subject.emtreeAsia
dc.subject.emtreeCancer combination chemotherapy
dc.subject.emtreeCancer mortality
dc.subject.emtreeCancer prognosis
dc.subject.emtreeCancer survival
dc.subject.emtreeCause of death
dc.subject.emtreeClinical effectiveness
dc.subject.emtreeContinuous infusion
dc.subject.emtreeDecreased appetite
dc.subject.emtreeDiarrhea
dc.subject.emtreeDrug dose reduction
dc.subject.emtreeDrug fatality
dc.subject.emtreeDrug megadose
dc.subject.emtreeDrug targeting
dc.subject.emtreeDrug tolerability
dc.subject.emtreeEsophagus cancer
dc.subject.emtreeEurope
dc.subject.emtreeFebrile neutropenia
dc.subject.emtreeGene mutation
dc.subject.emtreeHuman
dc.subject.emtreeHypokalemia
dc.subject.emtreeImmunohistochemistry
dc.subject.emtreeMedical decision making
dc.subject.emtreeMetastasis
dc.subject.emtreeMetastatic stomach cancer
dc.subject.emtreeMolecularly targeted therapy
dc.subject.emtreeMonotherapy
dc.subject.emtreeMucosa inflammation
dc.subject.emtreeMulticenter study (topic)
dc.subject.emtreeMultiple cycle treatment
dc.subject.emtreeNausea
dc.subject.emtreeNeutropenia
dc.subject.emtreeOncogene K ras
dc.subject.emtreeOverall survival
dc.subject.emtreePhase 2 clinical trial (topic)
dc.subject.emtreePhase 3 clinical trial (topic)
dc.subject.emtreePriority journal
dc.subject.emtreeProgression free survival
dc.subject.emtreeProtein expression
dc.subject.emtreeQuality of life
dc.subject.emtreeRandomized controlled trial (topic)
dc.subject.emtreeRash
dc.subject.emtreeReview
dc.subject.emtreeStomach cancer
dc.subject.emtreeStomach perforation
dc.subject.emtreeStomatitis
dc.subject.emtreeSurvival rate
dc.subject.emtreeSurvival time
dc.subject.emtreeThromboembolism
dc.subject.emtreeTreatment outcome
dc.subject.emtreeTreatment response
dc.subject.emtreeClinical trial (topic)
dc.subject.emtreeDrug delivery system
dc.subject.emtreePathology
dc.subject.emtreeStomach tumor
dc.subject.scopusRamucirumab; Rivoceranib; Line
dc.subject.wosOncology
dc.titleMetastatic gastric cancer treatment: A little slow but worthy progress
dc.typeReview
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Tıbbi Onkoloji Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama
İndir

Koleksiyonlar

İndeksli Yayınlar / Indexed Publications